SELLAS Life Sciences Group, Inc. (SLS) Stock

Healthcare · Biotechnology · Member of Other US Stocks

SELLAS Life Sciences Group, Inc. (SLS) closed at USD 11.88 on 2026-10-14, a change of +494 % over the past year, with a market capitalization of USD 2.29B.

SELLAS Life Sciences Group, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

SELLAS Life Sciences Group, Inc. key figures

Previous close

USD 11.88 (2026-10-14)

1-year change

+494 %

Market cap

USD 2.29B

Enterprise value

USD 2.15B

P/E ratio (trailing)

-59.68

P/E ratio (forward)

-113.40

EPS (trailing)

-0.19

EPS (forward)

-0.10

PEG ratio

n/a

Price to book

16.63

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

8.57

Employees

13

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for SELLAS Life Sciences Group, Inc. and compare it with other stocks.